Treatment of Chikungunya Virus (CHIKV) Using Targeted Immunotherapy
Chikungunya virus (CHIKV) is the most common mosquito-borne Alphavirus infecting humans worldwide. Up to date, there are no antiviral treatments or vaccines approved to treat or prevent CHIKV for which treatments remain symptomatic based on clinical manifestations. Hence, designing effective therapi...
Guardado en:
| Autores principales: | , , , , , |
|---|---|
| Formato: | Capítulo de libro |
| Lenguaje: | inglés |
| Publicado: |
IntechOpen
2021
|
| Materias: | |
| Acceso en línea: | https://www.intechopen.com/chapters/76721 |
| Etiquetas: |
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| _version_ | 1879164716186599424 |
|---|---|
| author | Biteghe, Fleury Augustin Nsole Toung, Chalomie Nyangone Ekome Ndong, Jean De La Croix Mungra, Neelakshi Dar, Tahir B. Kombe, Arnaud John Kombe |
| author_browse | Biteghe, Fleury Augustin Nsole Dar, Tahir B. Kombe, Arnaud John Kombe Mungra, Neelakshi Ndong, Jean De La Croix Toung, Chalomie Nyangone Ekome |
| author_facet | Biteghe, Fleury Augustin Nsole Toung, Chalomie Nyangone Ekome Ndong, Jean De La Croix Mungra, Neelakshi Dar, Tahir B. Kombe, Arnaud John Kombe |
| author_sort | Biteghe, Fleury Augustin Nsole |
| building | IntechOpen |
| collection | Acceso abierto |
| description | Chikungunya virus (CHIKV) is the most common mosquito-borne Alphavirus infecting humans worldwide. Up to date, there are no antiviral treatments or vaccines approved to treat or prevent CHIKV for which treatments remain symptomatic based on clinical manifestations. Hence, designing effective therapies to either prevent or treat CHIKV infection is of paramount importance. Interestingly, monoclonal antibodies (mAbs) are known to be significantly important in mediating protective immunity in CHIV infection. During the last decades, numerous animal studies have reported the protective and prophylactic efficacy of human and mouse anti-CHIKV mAbs isolated from convalescent patients. However, the therapeutic benefits of these anti-CHIKV mAbs can be limited by multiple factors. Thus, it becomes pertinent to better understand the CHIKV infection dynamics, mitigate the undesired mAbs-associated effects and improve therapies. In this review, we critically discuss CHIKV antiviral infectious mechanisms and address how the improved understanding of the latter may pave the way to better targeted immunotherapies. |
| doi_str_mv | 10.5772/intechopen.97811 |
| first_indexed | 2026-10-15T21:38:45Z |
| format | Book Chapter |
| fullrecord | <oai_dc:dc xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd"><identifier>intech-76721</identifier><datestamp>2021-09-22</datestamp>
<dc:title>Treatment of Chikungunya Virus (CHIKV) Using Targeted Immunotherapy</dc:title>
<dc:creator>Fleury Augustin Nsole Biteghe</dc:creator>
<dc:creator>Chalomie Nyangone Ekome Toung</dc:creator>
<dc:creator>Jean De La Croix Ndong</dc:creator>
<dc:creator>Neelakshi Mungra</dc:creator>
<dc:creator>Tahir B. Dar</dc:creator>
<dc:creator>Arnaud John Kombe Kombe</dc:creator>
<dc:subject>Health Sciences</dc:subject>
<dc:description>Chikungunya virus (CHIKV) is the most common mosquito-borne Alphavirus infecting humans worldwide. Up to date, there are no antiviral treatments or vaccines approved to treat or prevent CHIKV for which treatments remain symptomatic based on clinical manifestations. Hence, designing effective therapies to either prevent or treat CHIKV infection is of paramount importance. Interestingly, monoclonal antibodies (mAbs) are known to be significantly important in mediating protective immunity in CHIV infection. During the last decades, numerous animal studies have reported the protective and prophylactic efficacy of human and mouse anti-CHIKV mAbs isolated from convalescent patients. However, the therapeutic benefits of these anti-CHIKV mAbs can be limited by multiple factors. Thus, it becomes pertinent to better understand the CHIKV infection dynamics, mitigate the undesired mAbs-associated effects and improve therapies. In this review, we critically discuss CHIKV antiviral infectious mechanisms and address how the improved understanding of the latter may pave the way to better targeted immunotherapies.</dc:description>
<dc:publisher>IntechOpen</dc:publisher>
<dc:date>2021-09-22</dc:date>
<dc:type>Chapter, Part Of Book</dc:type>
<dc:identifier>https://www.intechopen.com/chapters/76721</dc:identifier>
<dc:identifier>doi:10.5772/intechopen.97811</dc:identifier>
<dc:language>en</dc:language>
<dc:relation>ISBN:978-1-83969-089-1</dc:relation>
<dc:rights>https://creativecommons.org/licenses/by/3.0/</dc:rights>
<dc:source>https://www.intechopen.com/books/9615 ; Chikungunya Virus - A Growing Global Public Health Threat</dc:source>
</oai_dc:dc> |
| id | intech-76721 |
| institution | IntechOpen |
| isbn | 978-1-83969-089-1 |
| language | English |
| last_indexed | 2026-10-15T21:38:45Z |
| publishDate | 2021 |
| publishDateRange | 2021 |
| publishDateSort | 2021 |
| publisher | IntechOpen |
| publisherStr | IntechOpen |
| record_format | oai_dc |
| spelling | intech-767212021-09-22 Treatment of Chikungunya Virus (CHIKV) Using Targeted Immunotherapy Fleury Augustin Nsole Biteghe Chalomie Nyangone Ekome Toung Jean De La Croix Ndong Neelakshi Mungra Tahir B. Dar Arnaud John Kombe Kombe Health Sciences Chikungunya virus (CHIKV) is the most common mosquito-borne Alphavirus infecting humans worldwide. Up to date, there are no antiviral treatments or vaccines approved to treat or prevent CHIKV for which treatments remain symptomatic based on clinical manifestations. Hence, designing effective therapies to either prevent or treat CHIKV infection is of paramount importance. Interestingly, monoclonal antibodies (mAbs) are known to be significantly important in mediating protective immunity in CHIV infection. During the last decades, numerous animal studies have reported the protective and prophylactic efficacy of human and mouse anti-CHIKV mAbs isolated from convalescent patients. However, the therapeutic benefits of these anti-CHIKV mAbs can be limited by multiple factors. Thus, it becomes pertinent to better understand the CHIKV infection dynamics, mitigate the undesired mAbs-associated effects and improve therapies. In this review, we critically discuss CHIKV antiviral infectious mechanisms and address how the improved understanding of the latter may pave the way to better targeted immunotherapies. IntechOpen 2021-09-22 Chapter, Part Of Book https://www.intechopen.com/chapters/76721 doi:10.5772/intechopen.97811 en ISBN:978-1-83969-089-1 https://creativecommons.org/licenses/by/3.0/ https://www.intechopen.com/books/9615 ; Chikungunya Virus - A Growing Global Public Health Threat |
| spellingShingle | Health Sciences Biteghe, Fleury Augustin Nsole Toung, Chalomie Nyangone Ekome Ndong, Jean De La Croix Mungra, Neelakshi Dar, Tahir B. Kombe, Arnaud John Kombe Treatment of Chikungunya Virus (CHIKV) Using Targeted Immunotherapy |
| title | Treatment of Chikungunya Virus (CHIKV) Using Targeted Immunotherapy |
| title_full | Treatment of Chikungunya Virus (CHIKV) Using Targeted Immunotherapy |
| title_fullStr | Treatment of Chikungunya Virus (CHIKV) Using Targeted Immunotherapy |
| title_full_unstemmed | Treatment of Chikungunya Virus (CHIKV) Using Targeted Immunotherapy |
| title_short | Treatment of Chikungunya Virus (CHIKV) Using Targeted Immunotherapy |
| title_sort | treatment of chikungunya virus chikv using targeted immunotherapy |
| topic | Health Sciences |
| url | https://www.intechopen.com/chapters/76721 |
| work_keys_str_mv | AT biteghefleuryaugustinnsole treatmentofchikungunyaviruschikvusingtargetedimmunotherapy AT toungchalomienyangoneekome treatmentofchikungunyaviruschikvusingtargetedimmunotherapy AT ndongjeandelacroix treatmentofchikungunyaviruschikvusingtargetedimmunotherapy AT mungraneelakshi treatmentofchikungunyaviruschikvusingtargetedimmunotherapy AT dartahirb treatmentofchikungunyaviruschikvusingtargetedimmunotherapy AT kombearnaudjohnkombe treatmentofchikungunyaviruschikvusingtargetedimmunotherapy |